Exploring genetic methods to improve liver recovery and lower cancer risk
Innovative Genetic Approaches to Enhance Liver Repopulation and Reduce Cancer Risk and Progression
This study is looking at how the liver heals after being hurt and how certain genes might help it recover and prevent cancer, with the hope of finding new treatments that could help people with liver issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10875276 on NIH RePORTER |
What this research studies
This research investigates how the liver responds to toxic injuries and the role of specific genetic factors in liver recovery and cancer prevention. By utilizing a cutting-edge screening platform, the team aims to evaluate the effects of various microRNAs on liver regeneration and the development of liver cancer. Patients may benefit from new therapeutic approaches that enhance liver healing and reduce the risk of hepatocellular carcinoma. The research involves testing genetic therapies in animal models to identify effective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of liver injury or those at risk for liver cancer due to underlying liver conditions.
Not a fit: Patients with stable liver function and no history of liver injury or cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that significantly improve liver recovery and reduce the risk of liver cancer for patients.
How similar studies have performed: Previous research has shown promise in using genetic approaches for liver treatment, indicating potential for success in this innovative approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kaestner, Klaus H — University of Pennsylvania
- Study coordinator: Kaestner, Klaus H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.